AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00022737
Drug: pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00022737
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01462006
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: randomized to drug or placebo, followed by washout, followed by crossover
Trial: NCT00196703
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004877
Drug: BMS-214662
RxNorm normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01584830
Drug: Regorafenib (BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
Trial: NCT03363139
Drug: Tirosin Kinase Inhibitors
RxNorm normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that received Tyrosin Kinase inhibitors and progressed
Trial: NCT00288002
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00288002
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00972322
Drug: MK-8245
RxNorm normalized name: MK-8245
DrugBank: MK-8245 (DB13024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8245 50 mg twice daily for 28 days
Trial: NCT01533753
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
Trial: NCT01533753
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
Trial: NCT00002720
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01372839
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Trial: NCT04454762
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral administration (40 mg daily, reduced dose 20 mg daily)
Trial: NCT01225380
Drug: GS-9190
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9190 capsule, 20 mg BID, 16 or 24 weeks
Trial: NCT01225380
Drug: GS-9256
RxNorm normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9256 capsule, 150 mg BID, 16 or 24 weeks
Trial: NCT04642469
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous administration of Durvalumab
Trial: NCT01225380
Drug: GS-9256
RxNorm normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9256 capsule, 150 mg BID, 24 weeks
Trial: NCT01225380
Drug: GS-9256 placebo
RxNorm normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching GS-9256 capsule BID, 24 weeks
Trial: NCT00243906
Drug: Recombinant tissue plasminogen activator
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
Trial: NCT01268904
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
Trial: NCT04400110
Drug: Amoxicillin and Clavulanic Acid in Oral Dose Form
RxNorm normalized name: Product containing amoxicillin and clavulanic acid in oral dose form (medicinal product form)
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/kg three times daily administered orally
Trial: NCT02859077
Drug: EGFR-TKI
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-TKI (gefitinib)
Trial: NCT02859077
Drug: Chemotherapy（pemetrexed/gemcitabine）
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy (pemetrexed/gemcitabine)
Trial: NCT02859077
Drug: Chemotherapy（carboplatin）
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy（carboplatin）
Trial: NCT04358432
Drug: AK102
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04358432
Drug: Statins and/or Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipid-lowering therapies
Trial: NCT03309163
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient-controlled intravenous analgesia with Tramadol
Trial: NCT01042938
Drug: Curcumin C3 Complex
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Trial: NCT03309163
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with Hydromorphone
Trial: NCT03309163
Drug: Ropivacaine (Epidural analgesia)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia with Ropivacaine.
Trial: NCT00725712
Drug: GSK1363089 (formerly XL880)
RxNorm normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-MET tyrosine kinase inhibitor
Trial: NCT03285607
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Standard of care
Trial: NCT04420247
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 days of treatment with Chloroquine + Standard Care
Trial: NCT04420247
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 days of treatment with Hydroxychloroquine + Standard Care
Trial: NCT03838731
Drug: REGN1908-1909
RxNorm normalized name: Immunoglobulin G4 [227-proline], anti-(Felis catus allergen Fel d1) (human monoclonal REGN1908 γ4-chain), disulfide with human monoclonal REGN1908 κ-chain, dimer
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) dose of REGN1908 and REGN1909
Trial: NCT01355874
Drug: Iferanserin
RxNorm normalized name: Iferanserin
DrugBank: Iferanserin (DB11686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
Trial: NCT03774615
Drug: Ferric maltol 30 mg (Feraccru®)
RxNorm normalized name: ferric maltol 30 MG
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Trial: NCT00269412
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01355874
Drug: Iferanserin + Placebo
DrugBank: Iferanserin (DB11686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
Trial: NCT04467918
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Already described
Trial: NCT04465266
Drug: Tolperisone
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00004139
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004139
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004139
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00089960
Drug: AMG 706
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
Trial: NCT02412735
Drug: Rexlemestrocel-L
RxNorm normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rexlemestrocel-L injection
Trial: NCT02412735
Drug: Rexlemestrocel-L + HA Mixture
RxNorm normalized name: brown mixture
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
Trial: NCT02015507
Drug: ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02015507
Drug: VX-661
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02015507
Drug: ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00756041
Drug: TAK-128
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-128 100 mg tablet, orally, once daily for up to 1 year.
Trial: NCT03405090
Drug: Combivent
RxNorm normalized name: Combivent
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
Trial: NCT03176264
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg every 2 weeks
Trial: NCT01508949
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Trial: NCT02228525
Drug: selinexor (KPT-330)
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01644864
Drug: 0.375% ROPIVACAINE
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00400998
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.
Trial: NCT01863147
Drug: Sitagliptin and acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
Trial: NCT02847429
Drug: Crenolanib
RxNorm normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01046461
Drug: Ramosetron, Aprepitant, Dexamethasone
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning
Trial: NCT01898377
Drug: Imatinib mesylate, Mycophenolate mofetil
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00224523
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02926222
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib is formulated as tablets of 40mg for oral administration.
Trial: NCT02926222
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine is formulated as tablets of 40mg for oral administration.
Trial: NCT00326053
Drug: Budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03257995
Drug: Indacaterol maleate
RxNorm normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 μg via Concept1 device
Trial: NCT03257995
Drug: Indacaterol acetate
RxNorm normalized name: indacaterol acetate
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 μg via Concept1 device
Trial: NCT05234840
Drug: platelet rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
Trial: NCT05234840
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone with 1% lidocaine, total of 2 ml
Trial: NCT02337478
Drug: Vincristine Sulfate Liposome
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via injection
Trial: NCT04320615
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Trial: NCT01022541
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above.
Trial: NCT00084604
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00084604
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03318211
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ampules of MgSo4 was given to only to control group after delivery
Trial: NCT03786094
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin alone
Trial: NCT01022541
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above.
Trial: NCT03786094
Drug: Balixafortide
RxNorm normalized name: Balixafortide
DrugBank: Balixafortide (DB15370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balixafortide + Eribulin
Trial: NCT03065075
Drug: Phenazopyridine
RxNorm normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenazopyridine 200 mg on morning of postoperative day 1
Trial: NCT04288518
Drug: SPECT or SPECT-CT with 99mTc-1-thio-D-glucose
RxNorm normalized name: Cardio-spect
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Trial: NCT04400487
Drug: Voxelotor
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg Tablet, Oral, With or Without Food
Trial: NCT03559062
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
Trial: NCT01450384
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01450384
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00137410
Drug: Celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00942864
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
Trial: NCT03272503
Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide 2mg tablets will be taken once daily.
Trial: NCT03903718
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg capsules orally twice a day from Day 2 to Day 7
Trial: NCT01594827
Drug: Inhaled Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Trial: NCT01594827
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Rifampin by mouth for 28 days~1. \>45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily
Trial: NCT01594827
Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. \>45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)
Trial: NCT01594827
Drug: Mupirocin Intranasal Creme
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
Trial: NCT01594827
Drug: 4% chlorhexidine gluconate liquid skin cleanser
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
Trial: NCT01221636
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for injection, Intravenous, 750 mg, 1 day